In a 17-year real-world psoriasis cohort, patients on IL-17i had 75% lower odds and IL-23i patients had 84% lower odds of developing #PsA vs TNF inhibitors. Is biologic class selection a PsA interception strategy? Prospective controlled trials are needed Abstr#072 @RheumNow https://t.co/jpdZjGK7VV

#Autoimmune #progressive #pulmonary #fibrosis Large Spanish registry ❎more mortality if not on #DMARDs ?underRx of proven #Rx with #antifibrotics Median survival post #dx #PPF 7.8 yrs Can we do better? #ABST POS0430 @RheumNow #EULAR2026 https://t.co/gP7apxfEPS

Multiparametric renal MRI in LN: Structural MRI can differentiate bet. active and stable dse Exudative = active inflamm In quanti analysis, low ADC values may reflect fibrosis. A potential non-invasive biomarker? OP092 @rheumNow #EULAR2026 https://t.co/IarTGOen7v

DIPSA RCT: diet in PsA 92 pts 3 arms Mediterranean vs DASH low-calorie vs standard advice Primary takeaway: amount of weight loss matters more than diet! -All groups lost modest weight 1–2.5 kg -All improved similarly in DAPSA -4 to -6 wk 24 -No differences for disease https://t.co/U0cxtdl2Yb

This retrospective cohort of NPSLE pts showed clinical assocs with MRI findings: Pts w/ focal symptoms - abn MRI Pts w/ diffuse symptoms - normal MRI except brain atrophy Interesting to know how this can aid in future mgt strategies for NPSLE OP093 @RheumNow #EULAR2026 https://t.co/omvdWk6EZK

TOGETHER PsA trial IXE+TIRZEPATIDE TZP vs. IXE alone RCT Obese or Overweight PsA IR to <3 bioDMARDs Primary endpoint ≥10% weight & ACR50 wk 36 31.7% IXE+TZP vs. 0.8% for IXE alone ACR50 IXE+TZP 33.5% & IXE 20.4%, p=0.02) No clear difference by gender/age/BMI/previous DMARDs https://t.co/zBcfpj2MF6

#OP087 explored cancer polygenic risk scores (PRS) in RA. RA was assoc with lower risks of breast and colorectal cancer across all PRS categories, while high prostate cancer PRS may identify RA patients with increased early prostate cancer diagnoses. @RheumNow #EULAR2026 https://t.co/WMqqSFADlW

68Ga-RGD PET/CT in PsA reveals large chunk of “silent” synovitis 15 pts 1020 joints 35% affected joints clinically silent PET signal correlation w/ disease burden: DAPSA (ρ=0.66) CRP (ρ=0.69) Pilot study — not confirmed with US Needs validation but intriguing signal #OP068 https://t.co/nhS7PDZN0A

#EULAR2026 OP077 Another promising CAR-T in autoimmunity. In a Phase II study, Rap-Cel autologous CD19 CAR-T (shorter infusion time ~2d & low dose) vs traditional CAR-T showed drug-free improvement in N=6 #IIM & N=6 #SSc patients. Safety similar to other CAR-Ts @RheumNow https://t.co/byNn5X8JGh

Treating inflammation and obesity in PsA with IXEKIZUMAB AND CONCOMITANT TIRZEPATIDE effective with no new safety signals OP069 @RheumNow #EULAR2026 https://t.co/rkhYvZWpHn

TOGETHER-PsA :ACR50 was already significantly higher with IXE+TZP as early as Week 4 (11.1% vs 3.9%, p=0.029). The metabolic and anti-inflammatory effects of GLP-1/GIP agonism may act synergistically Abstr#069 @RheumNow #EULAR2026 https://t.co/NBQ6CccuCn

TOGETHER PsA trial IXE+TIRZEPATIDE TZP vs. IXE alone RCT Obese or Overweight PsA IR to <3 bioDMARDs Primary endpoint ≥10% weight & ACR50 wk 36 31.7% IXE+TZP vs. 0.8% for IXE alone ACR50 IXE+TZP 33.5% & IXE 20.4%, p=0.02) No clear difference by gender/age/BMI/previous DMARDs https://t.co/lFbeb85b9Y

Cancer risk with JAK inhibitors remains a major focus at #EULAR2026. In #OP086, analysis from 14 international RA registries and >60000 treatment courses found no statistically significant increase in overall or subtype-specific malignancy risk with JAKi versus TNFi. @RheumNow https://t.co/JeOmTufYwo